ReCor Medical adds another $12m for trial of Paradise renal denervation device

August 16, 2017 By Brad Perriello Leave a Comment

ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning.

In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasound waves rather than radiofrequency ablation of nerves lining the renal artery to treat high blood pressure. ReCor won an investigational device exemption from the FDA in February 2016 for the Radiance-HTN study, which launched in April of that year.

The sham-controlled trial consists of two 60-day arms, he said: One, the “Solo” cohort, evaluating the Paradise treatment in patients with moderate hypertension who take one or two drugs for it, and a second called “Trio” investigating the treatment in patients with resistant hypertension who take three or more medications.

Weiss said the study design calls for the Solo cohort to stop taking blood pressure medications for a month before being randomized to either Paradise or a sham procedure. The Trio group are taken off of their anti-hypertensive cocktail, stabilized for a month and then given the three-drug Exforge HCT pill made by Novartis before being randomized to treatment or sham. The endpoint is mean reduction in average daytime ambulatory systolic blood pressure at 60 days; there are 146 patients in each cohort, he said.

“We’ve had an overwhelming amount of interest in the [Solo] study,” Weiss told us, noting that some 200,000 people have expressed interest in joining the trial. “We have as many patients signing up as our centers can handle. We’ve enrolled 500 total and 100 have already been randomized.”

The Otuska infusion will largely be used to complete Solo, with outcome data expected “this time next year, perhaps earlier,” he said. Some of the funds will go toward the Trio portion of the study, but as there are many fewer patients in that population, meaning slower enrollment, more cash will be needed to see it to completion, Weiss added.

“That trial is also enrolling well, but will take another six months [to finish Trio] beyond the finish of the Solo study,” he said.

Last year’s deal with Otsuka also gave that company the right to run Paradise studies in Asia. Weiss told us that ReCor’s Japanese partner, which led ReCor’s $15 million Series D in April 2015, has trials under way in Japan and South Korea.

It’s not the 1st time Otsuka has inked a deal with a medtech concern. In April 2016 the FDA issued a complete response letter requesting more information about the combination of Proteus Digital Health‘s “smart pill” and Otsuka’s Abilify anti-depressant drug.

Registration is Open for DeviceTalks Boston

Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.

REGISTER NOW

Medical device cybersecurity: It’s time to get real
Medical device makers, regulators and healthcare delivery organizations are increasingly working together to strengthen cybersecurity. But are they doing enough? Almost no one in the medtech industry disputes the vulnerability posed by cyberattacks. How to go about boosting security is another matter – one on which those stakeholders have recently stepped up their collaboration. One… […]
Can a lifetime guarantee boost value-based care?
Swiss orthopedics company Medacta International and Geisinger Health System have said they will pilot a lifetime guarantee program for knee replacement surgeries. The program will cover full costs for screened Geisinger Health Plan members who receive knee replacement surgery while also ensuring reimbursement for any associated future care the patients may incur throughout their lifetimes.… […]
Compounding Solutions launches new tie-layer resin
Compounding Solutions (Lewiston, Maine) recently announced that it has launched a new tie-layer resin for the medical device industry. ReZilok Rx is meant for the manufacturing of multilayer co-extruded medical films and catheter tubing, the company said in a February announcement. Compounding Solutions’ R&D team developed ReZilok Rx as a linear low-density polyethylene grafted with… […]
GI Dynamics touts results of U.K. study
GI Dynamics (ASX:GID) said a retrospective study of its EndoBarrier device for patients with type 2 diabetes and obesity shows a significant reduction in HbA1c, weight, liver fat and cardiovascular disease (CVD) risks as well as a reduction in the need for insulin in some patients. The EndoBarrier device is a plastic gut sleeve designed… […]
Think Surgical, United Orthopedic join forces for global sales
Think Surgical and United Orthopedic have announced a global joint marketing agreement of Think’s Active robotic system and United’s U2 knee system. Think’s Active robotic system consists of a 3D pre-surgical planning workstation and its computer-assisted Active robot. Its use in total knee arthroplasty is the subject of an FDA investigational device exemption study, with… […]
FDA ramps up scrutiny of materials in medical devices
The FDA said today it has begun more closely scrutinizing the roles of certain materials associated with harm to patients who have breast implants, nitinol-containing devices, metal-on-metal hip implants and devices made from animal-derived substances. It’s the latest in a series of statements the agency has issued following increasingly harsh public criticism of its efforts… […]
AxioMed receives CE Mark approval for Cervical Freedom
AxioMed has received CE Mark approval for its viscoelastic disc replacement device. The Cervical Freedom’s total disc replacement is now eligible for commercialization in the European, Asian, Latin American and Australian markets and where it has already been TGA approved. AxioMed’s Freedom Cervical disc responds to loading and moves in three dimensions like the human… […]
10 orthopedic products from AAOS 2019 you need to know
The American Academy of Orthopaedic Surgeons (AAOS) annual meeting in Las Vegas is abuzz about robotics, according to industry analysts from SVB Leerink. While the SVB Leerink analysts termed Stryker’s (NYSE:SYK) Mako platform “best-in-class,” robotically assisted orthopedic surgery is an expanding category. Other major orthopedics companies are using this week’s AAOS meeting to introduce new… […]
Webinar: Here’s how you create better healthcare experiences through human-centered design
Wednesday, April 17, 2019 2 p.m. Eastern time / 11 a.m. Pacific time The greatest challenges in healthcare are at the human level. Diet, fitness, medication adherence and regular check-ups can all be influenced by our personal relationships. While today’s technology can impede these human-to-human interactions, following a human-centered approach gives organizations the power to… […]
Orthopaedic Implant Co. enters sports medicine market with new suture anchor
The Orthopaedic Implant Company (“OIC”) said it has launched a 5.5mm PEEK suture anchor system for orthopedic surgery. The OIC 5.5mm suture anchor accommodates up to three #2 sutures of any brand, resulting in an implant that offers flexibility, at a cost-effective price, according to the Reno, Nev.-based company. The anchors are made of biocompatible… […]
Oberd launches AI-assisted tech for gathering outcome data
Patient-reported outcomes vendor Oberd said it has launched software designed to reduce a patient’s time in completing outcomes surveys for orthopedic procedures. Patient-reported outcomes can help quantify the value of a healthcare provider’s services. Columbia, Mo.-based Oberd’s computer-adaptive test (CAT) software has been developed and validated for all of the outcomes surveys approved by the… […]